source
- Mid-size pharma firms drive surge in biopharma M&A activityThe article notes that 2026 is shaping up as one of the busiest years for biopharma mergers and acquisitions on record. Unlike previous years dominated by large multinational companies, a broader…
- Biopharma M&A stays robust as companies shift focus from megadeals to smaller targetsThe article notes that despite a slowdown in large megadeals, overall merger and acquisition activity in the biopharma sector remains strong. Companies are adopting multi‑pronged strategies to add…